Breast Cancer

plasmaMATCH Findings Play an Important Role in the Breast Cancer Setting

April 30, 2020

Joyce A. O'Shaughnessy, MD, discusses the phase II plasmaMATCH trial, which investigated plasma-based molecular profiling of patients with advanced breast cancer to inform therapeutic choices.

Managing Symptoms of Diarrhea Improves Medication Adherence in Patients Treated With Abemaciclib

April 23, 2020

Dose escalation may be beneficial for patients starting treatment regimens with a high incidence of toxicities that may lead to abrupt patient self-discontinuation.

FDA Grants Accelerated Approval to Sacituzumab Govitecan in mTNBC

April 22, 2020

"The approval of sacituzumab govitecan, the first ADC approved specifically for metastatic TNBC, an aggressive cancer with a poor prognosis and few effective therapies, will give clinicians a novel tool for treating patients with this disease."

Talazoparib Toxicities Manageable in gBRCA-Mutated HER2-Negative Advanced Breast Cancer

April 20, 2020

Safety data from the phase III EMBRACA trial were recently published. Talazoparib appears to be safe with manageable toxicities in patients with germline BRCA-mutated HER2-negative advanced breast cancer.

FDA Approves Tucatinib Plus Trastuzumab/Capecitabine in HER2-Positive Breast Cancer

April 17, 2020

The FDA granted accelerated approval for tucatinib tablets in combination with trastuzumab and capecitabine as treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases who have received one or more prior anti-HER2-based regimens in the metastatic setting. The approval comes 4 months ahead of the targeted action date from the FDA’s Real-Time Oncology Review.

RIBECCA Trial Confirms Role of Ribociclib Combination in HR+ HER2-Negative Breast Cancer

April 17, 2020

In an interview with Targeted Oncology, Andreas Hartkopf, MD, discussed the findings from the RIBECCA trial and the key takeaways from these data for patients with HR-positive HER2-negative breast cancer.

Molecular Drivers of Cancer to Be Focus of Discussions at Breast Cancer Conferences

April 16, 2020

As the breast cancer setting quickly changes with each advancement, physicians who care for these patients will need to know how to apply these emerging treatments to the standards of care in their practice.

A 59-Year-Old Woman With HER2+ De Novo Metastatic Breast Cancer

April 16, 2020

A 59-Year-Old Woman With HER2+ De Novo Metastatic Breast Cancer

Women With Indigenous American Ancestry Have Higher Odds of HER2-Positive Breast Cancer

April 08, 2020

Indigenous American ancestry has been linked to an increased incidence of HER2-positive breast cancer, according to the Peruvian Genetics and Genomics of Breast Cancer Study study published in Cancer Research.

FDA Grants Pembrolizumab Priority Review for TMB-High Tumors

April 07, 2020

The FDA has accepted and granted a priority review to a supplemental Biologics License Application for pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic solid tumors with tissue tumor mutational burden-high who have progressed following prior treatment and who have no satisfactory alternative treatment options.